Fig. 2From: Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective studyDuration of response with crizotinib treatment in 14 patients. Arrow indicates continuation to crizotinib treatmentBack to article page